Kisspeptin-10: Discovery and Research History

Introduction

The scientific history of kisspeptin-10 (KP-10) is a study in serendipitous convergence between two apparently unrelated fields — cancer metastasis biology and reproductive neuroendocrinology. The KISS1 gene was identified as a metastasis suppressor nearly a decade before any of its protein products were connected to reproductive hormone regulation. The subsequent identification of kisspeptins as ligands for an orphan receptor, and the clinical genetic demonstration that this receptor is essential for pubertal development, represent pivotal moments in reproductive biology that generated a productive and still-active research literature.

Discovery Period: KISS1 as a Metastasis Suppressor (1996)

The gene now designated KISS1 was first cloned and reported in 1996 by Lee and colleagues at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania [1]. The research program aimed to identify genes responsible for the metastasis-suppressing properties observed in chromosome 6/human melanoma cell hybrids. Using modified subtractive hybridization, the investigators isolated a novel cDNA — which they named KiSS-1 — expressed in non-metastatic hybrid cells but absent or reduced in metastatic lines.

The gene name was selected partly to reflect its function as a metastasis suppressor and partly as an informal tribute to its place of discovery — Hershey, Pennsylvania, home of the Hershey Company's chocolate products marketed under the name Kisses [1]. The designation proved durable, and the chocolate-inspired etymology is documented in the primary literature. For several years, KISS1 was studied primarily in the context of cancer biology, with published reports examining its expression across tumor types and its role in suppressing metastatic spread in cell and animal models.

Identification of Kisspeptins as GPR54 Ligands (2001)

The connection between KISS1 and G-protein-coupled receptor pharmacology was established in 2001 through simultaneous independent discovery by three research groups — a convergence that illustrates the productive momentum of orphan receptor deorphanization programs in the early 2000s.

Ohtaki and colleagues at Takeda Chemical Industries, Kyoto, Japan, reported in Nature in June 2001 that the KISS1 gene product — which they termed "metastin" in recognition of its metastasis-suppressor function — was the endogenous ligand for the orphan G-protein-coupled receptor GPR54 [2]. The Ohtaki group isolated the peptide from human placenta, characterized its sequence, and demonstrated its activity at GPR54 using calcium mobilization assays in transfected cells.

Kotani and colleagues, publishing in the Journal of Biological Chemistry in the same period, independently reported the same ligand–receptor pairing, naming the peptides "kisspeptins" and characterizing four biologically active fragments: kisspeptin-54, kisspeptin-14, kisspeptin-13, and kisspeptin-10 [3]. Their report established that all four fragments shared equivalent receptor binding affinity and activation efficacy, and that biological activity resided in the shared C-terminal decapeptide sequence — the fragment now designated KP-10. The receptor pharmacology and downstream signaling characterized from this ligand identification work is covered in the mechanism of action article.

Muir and colleagues, working from the perspective of the then-orphan receptor (which they had designated AXOR12), published a parallel characterization in the Journal of Biological Chemistry demonstrating the same ligand identification from a receptor-first rather than ligand-first discovery approach [4]. The name "kisspeptin" coined by Kotani et al. achieved consensus in the field, and the receptor was formally renamed KISS1R from its previous GPR54 designation by the IUPHAR nomenclature committee in 2010 [5].

Early Research: From Orphan Deorphanization to Reproductive Genetics (2001–2005)

The initial published reports on kisspeptin–KISS1R focused on receptor distribution and pharmacological characterization. GPR54 was found to be expressed in the hypothalamus, pituitary, placenta, and other peripheral tissues. The physiological function of this receptor–ligand pair beyond its role in cancer metastasis suppression remained an open question in the early 2000s — one that a wave of genetic and pharmacological research would answer decisively.

The pivotal shift came in 2003, when two independent clinical genetics groups identified inactivating mutations in GPR54 as the cause of idiopathic hypogonadotropic hypogonadism (IHH) in human pedigrees — a condition characterized by absent or incomplete pubertal development due to insufficient GnRH secretion.

Seminara and colleagues at Massachusetts General Hospital (Harvard Medical School) published their findings in the New England Journal of Medicine in October 2003 [6]. Studying an extended consanguineous pedigree and generating a Gpr54-null mouse model, the investigators reported that loss-of-function mutations in GPR54 caused reproductive failure — sexual infantilism and absence of pubertal development in both humans and mice — establishing GPR54 as an essential regulator of the reproductive axis and founding a new subdiscipline in reproductive neuroendocrinology.

De Roux and colleagues in France simultaneously reported an inactivating GPR54 mutation in an inbred family with hypogonadotropic hypogonadism, published in the Proceedings of the National Academy of Sciences [7]. The de Roux group identified a large deletion in the GPR54 locus through linkage analysis, independently confirming the connection between GPR54 signaling and human pubertal development. These twin 2003 publications — from independent groups using complementary approaches — redirected the field toward HPG axis research and established loss-of-function GPR54 genetics as a human model for studying GnRH-dependent puberty.

The anatomical and mechanistic basis for kisspeptin's effect on GnRH secretion was established through research published between 2003 and 2005. Studies in rodent models documented KISS1R expression on GnRH neurons and demonstrated that kisspeptin administration produced GnRH release and activation of the HPG axis. Smith and colleagues (2005) characterized hypothalamic KISS1 mRNA expression in the arcuate nucleus (ARC) and anteroventral periventricular nucleus (AVPV) of rodents, reporting opposing regulation of KISS1 expression by gonadal steroids in these two regions — providing a mechanistic basis for gonadal steroid feedback on GnRH secretion via kisspeptin neurons [8].

The Clinical Research Program (2005–Present)

The research program at Imperial College London, led by Waljit Dhillo and colleagues, has produced a sustained series of controlled human studies administering kisspeptin isoforms to healthy volunteers and defined research populations. This history parallels the clinical research trajectory of other hypothalamic GPCR-targeted neuropeptides, including oxytocin acetate, whose formal research program also emerged from convergent pharmacological and clinical genetics findings. This program, running from 2005 onward, has characterized the neuroendocrine responses to kisspeptin-54 and KP-10 in healthy men and women, examined effects across the menstrual cycle, and explored responses in individuals with various hypothalamic phenotypes. Studies from this program have been published in peer-reviewed endocrinology journals including the Journal of Clinical Endocrinology and Metabolism and Human Reproduction [9, 10].

A research focus on kisspeptin-54 as a potential trigger for oocyte maturation emerged from this program in the 2010s. Pilot and randomized controlled trials exploring this application were published from the Dhillo group, reflecting the broader investigational trajectory of kisspeptin research [10]. These studies involved kisspeptin-54 rather than KP-10, but illustrate the range of investigational contexts in which kisspeptin isoforms have been explored.

Kisspeptin isoforms have been studied under Investigational New Drug (IND) applications in the US and equivalent ethics-approved frameworks in the UK and Europe. The sustained investment by multiple research institutions in kisspeptin pharmacology across nearly two decades reflects the scientific community's recognition of KISS1R as a well-validated and pharmacologically tractable target in HPG axis research.

Current Research Landscape

The contemporary KP-10 research landscape encompasses several distinct threads. Structural biology and computational chemistry research continues to refine understanding of KP-10's receptor binding mode and has informed development of modified analogs with extended half-lives and improved in vivo pharmacokinetic profiles. The KNDy neuron model of GnRH pulse generation — in which kisspeptin is the output signal from arcuate nucleus interneurons co-expressing neurokinin B and dynorphin — has generated active research into how KP-10 acts within this circuit and how pharmacological modulation of KISS1R can probe the circuit's function in real time.

Research interest in KISS1R outside the hypothalamus has expanded, with published studies examining kisspeptin's role in placental biology, the cardiovascular system, and cancer biology. These non-HPG axis aspects of kisspeptin biology add pharmacological complexity to interpretation of systemic KP-10 administration studies and represent emerging directions for the field. The depth and breadth of the published kisspeptin literature — from in vitro pharmacology through controlled human studies — positions kisspeptin-10 as one of the better-characterized neuropeptide research tools in neuroendocrinology.

References

1. Lee JH, Miele ME, Hicks DJ, Phillips KK, Trent JM, Weissman BE, Welch DR. KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst. 1996;88(23):1731-1737. PMID: 8944003. DOI: 10.1093/jnci/88.23.1731

2. Ohtaki T, Shintani Y, Honda S, Matsumoto H, Hori A, Kanehashi K, et al. Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature. 2001;411(6837):613-617. PMID: 11385580. DOI: 10.1038/35079135

3. Kotani M, Detheux M, Vandenbogaerde A, Communi D, Vanderwinden JM, Le Poul E, et al. The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. J Biol Chem. 2001;276(37):34631-34636. PMID: 11457843. DOI: 10.1074/jbc.M104847200

4. Muir AI, Chamberlain L, Elshourbagy NA, Michalovich D, Moore DJ, Calamari A, et al. AXOR12, a novel human G protein-coupled receptor, activated by the peptide KiSS-1. J Biol Chem. 2001;276(31):28969-28975. PMID: 11387442. DOI: 10.1074/jbc.M102743200

5. Pinilla L, Aguilar E, Dieguez C, Millar RP, Tena-Sempere M. Kisspeptins and reproduction: physiological roles and regulatory mechanisms. Physiol Rev. 2012;92(3):1235-1316. PMID: 22811428. DOI: 10.1152/physrev.00037.2010

6. Seminara SB, Messager S, Chatzidaki EE, Thresher RR, Acierno JS Jr, Shagoury JK, et al. The GPR54 gene as a regulator of puberty. N Engl J Med. 2003;349(17):1614-1627. PMID: 14573733. DOI: 10.1056/NEJMoa035322

7. de Roux N, Genin E, Carel JC, Matsuda F, Chaussain JL, Milgrom E. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci USA. 2003;100(19):10972-10976. PMID: 12944565. DOI: 10.1073/pnas.1834399100

8. Smith JT, Cunningham MJ, Rissman EF, Clifton DK, Steiner RA. Regulation of Kiss1 gene expression in the brain of the female mouse. Endocrinology. 2005;146(9):3686-3692. PMID: 15919743. DOI: 10.1210/en.2005-0488

9. Chan YM, Butler JP, Pinnell NE, Pralong FP, Crowley WF Jr, Ren C, et al. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. J Clin Endocrinol Metab. 2011;96(8):E1315-E1319. PMID: 21632807. DOI: 10.1210/jc.2011-0265

10. Abbara A, Jayasena CN, Christopoulos G, Narayanaswamy S, Izzi-Engbeaya C, Nijher GM, et al. Efficacy of kisspeptin-54 to trigger oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) therapy. J Clin Endocrinol Metab. 2015;100(9):3322-3331. PMID: 26168278. DOI: 10.1210/JC.2015-2332